<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Aim Vaccine Co., Ltd. Class H — News on 6ix</title>
<link>https://6ix.com/company/aim-vaccine-co-ltd</link>
<description>Latest news and press releases for Aim Vaccine Co., Ltd. Class H on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 05 Feb 2026 23:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/aim-vaccine-co-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68368d1178dffbe2df16d2b5.webp</url>
<title>Aim Vaccine Co., Ltd. Class H</title>
<link>https://6ix.com/company/aim-vaccine-co-ltd</link>
</image>
<item>
<title>World's First Serum-Free Iterative Rabies Vaccine from AIM Successfully Passes On-Site Registration Inspections and Is Imminent for Launch</title>
<link>https://6ix.com/company/aim-vaccine-co-ltd/news/worlds-first-serum-free-iterative-233000600</link>
<guid isPermaLink="true">https://6ix.com/company/aim-vaccine-co-ltd/news/worlds-first-serum-free-iterative-233000600</guid>
<pubDate>Thu, 05 Feb 2026 23:30:00 GMT</pubDate>
<description>Poised to Fill the Global Market Gap, the Serum-Free Iterative Rabies Vaccine Approaches a Critical Milestone in Commercialization. AIM Vaccine (06660.HK), a leading domestic vaccine company, announced on February 5 that its wholly-owned subsidiary AIM Rongyu's world's first independently developed serum-free iterative rabies vaccine has successfully passed the National Medical Products Administration (NMPA) on-site inspection for drug clinical trials and the on-site inspection for drug registra</description>
</item>
<item>
<title>AIM Vaccine's 20-Valent Pneumococcal Conjugate Vaccine Receives Clinical Approval, Upgraded Iterative Major Product Expected to Seize Domestic Opportunities</title>
<link>https://6ix.com/company/aim-vaccine-co-ltd/news/aim-vaccines-20-valent-pneumococcal-conjugate-vaccine-receives-clinical-approval-upgraded-iterative-major-product-expected-to-seize-domestic-opportunities</link>
<guid isPermaLink="true">https://6ix.com/company/aim-vaccine-co-ltd/news/aim-vaccines-20-valent-pneumococcal-conjugate-vaccine-receives-clinical-approval-upgraded-iterative-major-product-expected-to-seize-domestic-opportunities</guid>
<pubDate>Tue, 20 Jan 2026 00:00:00 GMT</pubDate>
<description>AIM Vaccine (06660.HK), a leading domestic vaccine company, announced on January 19 that it has developed an optimized upgraded version of its iterative 20-valent pneumococcal conjugate vaccine, which has recently received clinical trial approval from the National Medical Products Administration. This marks a further enrichment and enhancement of AIM's research and development pipeline in the pneumococcal vaccine field.</description>
</item>
<item>
<title>AIM's Iterative Process High-Efficiency Diploid Rabies Vaccine Completes Phase III Clinical Trials, Efficacy Significantly Higher than Existing Market Products</title>
<link>https://6ix.com/company/aim-vaccine-co-ltd/news/aims-iterative-process-high-efficiency-003000462</link>
<guid isPermaLink="true">https://6ix.com/company/aim-vaccine-co-ltd/news/aims-iterative-process-high-efficiency-003000462</guid>
<pubDate>Thu, 15 Jan 2026 00:30:00 GMT</pubDate>
<description>AIM Vaccine (06660.HK), a leading domestic vaccine company, announced on January 15 that its research and development of the iterative process high-efficiency diploid rabies vaccine has successfully completed the Phase III clinical site work. This marks the official entry of the vaccine into a new phase, laying a solid foundation for future commercialization. At this critical juncture where the vaccine industry is shifting from "scale expansion" to "value competition," AIM's iterative rabies vac</description>
</item>
<item>
<title>AIM Vaccine Forecasts Surge in Stock Performance: Innovations Reinforce Leadership in Vaccine Sector</title>
<link>https://6ix.com/company/aim-vaccine-co-ltd/news/aim-vaccine-forecasts-surge-in-stock-performance-innovations-reinforce-leadership-in-vaccine-sector</link>
<guid isPermaLink="true">https://6ix.com/company/aim-vaccine-co-ltd/news/aim-vaccine-forecasts-surge-in-stock-performance-innovations-reinforce-leadership-in-vaccine-sector</guid>
<pubDate>Wed, 27 Aug 2025 23:45:00 GMT</pubDate>
<description>AIM Vaccine (06660.HK), a leading domestic vaccine company, announced today the release of its 2025 interim report, showcasing robust revenue growth. With major products entering the market phase, R&D costs are decreasing, and operational expenditures are being optimized. Four core innovative products are poised for commercialization, and significant advancements have been made in overseas market expansion. Two mRNA technology vaccines have simultaneously received clinical trial approvals in bot</description>
</item>
<item>
<title>AIM Vaccine's Next-Gen mRNA Shingles Vaccine Secures Clinical Approvals in Both PRC and U.S. ,mRNA Platform Advantages Shine Through</title>
<link>https://6ix.com/company/aim-vaccine-co-ltd/news/aim-vaccines-next-gen-mrna-shingles-vaccine-secures-clinical-approvals-in-both-prc-and-us-mrna-platform-advantages-shine-through</link>
<guid isPermaLink="true">https://6ix.com/company/aim-vaccine-co-ltd/news/aim-vaccines-next-gen-mrna-shingles-vaccine-secures-clinical-approvals-in-both-prc-and-us-mrna-platform-advantages-shine-through</guid>
<pubDate>Mon, 19 May 2025 00:30:00 GMT</pubDate>
<description>While global giants like Moderna and BioNTech apply mRNA technology to broader disease markets, PRC's mRNA frontrunner is keeping pace. AIM Vaccine (06660.HK), a leading domestic vaccine company, announced today that its self-developed mRNA shingles vaccine has received clinical trial approval from PRC's Center for Drug Evaluation (CDE), following its U.S. FDA clearance in March this year. The vaccine has demonstrated significantly stronger humoral and cellular immunity compared to international</description>
</item>
<item>
<title>AIM's Serum-Free Iterative Rabies Vaccine Receives Acceptance for Market Registration; Institutions Predict Significant Valuation Recovery Potential for the Company</title>
<link>https://6ix.com/company/aim-vaccine-co-ltd/news/aims-serum-free-iterative-rabies-vaccine-receives-acceptance-for-market-registration-institutions-predict-significant-valuation-recovery-potential-for-the-company</link>
<guid isPermaLink="true">https://6ix.com/company/aim-vaccine-co-ltd/news/aims-serum-free-iterative-rabies-vaccine-receives-acceptance-for-market-registration-institutions-predict-significant-valuation-recovery-potential-for-the-company</guid>
<pubDate>Tue, 08 Apr 2025 00:00:00 GMT</pubDate>
<description>AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, announced on April 7, 2025 that the company's research and development of the serum-free iterative rabies vaccine has received an "Acceptance Notice" from the National Medical Products Administration for market registration. In addition, the vaccine has obtained the corresponding product production license. Currently, there are no serum-free rabies vaccines approved for sale in the global market, and this product is expected to bec</description>
</item>
<item>
<title>AIM Vaccine reduces losses by nearly 90% in 2024, with the iterative major product series opening up space for explosive growth in performance</title>
<link>https://6ix.com/company/aim-vaccine-co-ltd/news/aim-vaccine-reduces-losses-by-nearly-90percent-in-2024-with-the-iterative-major-product-series-opening-up-space-for-explosive-growth-in-performance</link>
<guid isPermaLink="true">https://6ix.com/company/aim-vaccine-co-ltd/news/aim-vaccine-reduces-losses-by-nearly-90percent-in-2024-with-the-iterative-major-product-series-opening-up-space-for-explosive-growth-in-performance</guid>
<pubDate>Mon, 31 Mar 2025 00:00:00 GMT</pubDate>
<description>AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published its 2024 Annual Results announcement on March 30, 2025, the company recorded revenues of RMB 1,285 million in 2024, an increase of 8.2% compared to the previous year, with significant sales growth in its hepatitis B vaccine, hepatitis A vaccine, and quadrivalent meningococcal vaccine. The annual loss narrowed to RMB 278 million, demonstrating a substantial reduction of 85.7% in net losses, signaling a strong indication of</description>
</item>
<item>
<title>AIM Vaccine's mRNA Shingles Vaccine Approved by the US FDA to Begin Clinical Trials, AI-Enabled mRNA Major Vaccine Product Development Accelerates</title>
<link>https://6ix.com/company/aim-vaccine-co-ltd/news/aim-vaccines-mrna-shingles-vaccine-approved-by-the-us-fda-to-begin-clinical-trials-ai-enabled-mrna-major-vaccine-product-development-accelerates</link>
<guid isPermaLink="true">https://6ix.com/company/aim-vaccine-co-ltd/news/aim-vaccines-mrna-shingles-vaccine-approved-by-the-us-fda-to-begin-clinical-trials-ai-enabled-mrna-major-vaccine-product-development-accelerates</guid>
<pubDate>Mon, 24 Mar 2025 00:00:00 GMT</pubDate>
<description>AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on March 23, 2025, the company's independently developed mRNA shingles vaccine has recently received clinical trial approval from the U.S. Food and Drug Administration (FDA). As of now, AIM has obtained FDA approval to begin clinical trials for two major mRNA vaccine products: the mRNA shingles vaccine and the mRNA RSV vaccine.</description>
</item>
<item>
<title>AIM Vaccine reported a significant reduction in losses for 2024, with several major products set to launch that are expected to drive substantial revenue growth</title>
<link>https://6ix.com/company/aim-vaccine-co-ltd/news/aim-vaccine-reported-a-significant-reduction-in-losses-for-2024-with-several-major-products-set-to-launch-that-are-expected-to-drive-substantial-revenue-growth</link>
<guid isPermaLink="true">https://6ix.com/company/aim-vaccine-co-ltd/news/aim-vaccine-reported-a-significant-reduction-in-losses-for-2024-with-several-major-products-set-to-launch-that-are-expected-to-drive-substantial-revenue-growth</guid>
<pubDate>Mon, 17 Mar 2025 06:30:00 GMT</pubDate>
<description>AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on March 17, 2025, the company's performance in 2024 showed a significant reduction in losses. Preliminary assessments indicate that the company's revenue is expected to be between RMB 1.25 billion and RMB 1.3 billion, representing a growth of 5% to 9% compared to the previous year. The net loss is projected to be between RMB 250 million and RMB 290 million, which is a reduction of 85% to 87% compared to t</description>
</item>
<item>
<title>AIM Vaccine's Serum-Free Iterative Rabies Vaccine Has Received Production License and Will Submit for Market Registration</title>
<link>https://6ix.com/company/aim-vaccine-co-ltd/news/aim-vaccines-serum-free-iterative-rabies-vaccine-has-received-production-license-and-will-submit-for-market-registration</link>
<guid isPermaLink="true">https://6ix.com/company/aim-vaccine-co-ltd/news/aim-vaccines-serum-free-iterative-rabies-vaccine-has-received-production-license-and-will-submit-for-market-registration</guid>
<pubDate>Tue, 11 Mar 2025 23:53:00 GMT</pubDate>
<description>AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on March 12, 2025, the company's serum-free iterative rabies vaccine has recently obtained the production license for serum-free rabies vaccine and will submit for market registration. This product is expected to be the first serum-free rabies vaccine on the global market, marking a significant technological breakthrough for AIM Vaccine and further solidifying the company's global leadership position in th</description>
</item>
<item>
<title>AIM Vaccine's Iteratively Upgraded Diploid Rabies Vaccine Approved for Clinical Trials, Showing Significantly Higher Efficacy than Marketed Diploid Rabies Vaccines</title>
<link>https://6ix.com/company/aim-vaccine-co-ltd/news/aim-vaccines-iteratively-upgraded-diploid-rabies-vaccine-approved-for-clinical-trials-showing-significantly-higher-efficacy-than-marketed-diploid-rabies-vaccines</link>
<guid isPermaLink="true">https://6ix.com/company/aim-vaccine-co-ltd/news/aim-vaccines-iteratively-upgraded-diploid-rabies-vaccine-approved-for-clinical-trials-showing-significantly-higher-efficacy-than-marketed-diploid-rabies-vaccines</guid>
<pubDate>Mon, 10 Mar 2025 00:00:00 GMT</pubDate>
<description>AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on March 9, 2025, the company's research and development of a diploid rabies vaccine has recently received the Clinical Trial Approval Notice from the National Medical Products Administration. This product is an upgraded version of the diploid rabies vaccine, featuring significantly high efficacy, marking a major iterative upgrade in the global rabies vaccine technology field. Animal trials have shown that</description>
</item>
<item>
<title>AIM Vaccine's mRNA RSV Vaccine Approved for U.S. Clinical Trials</title>
<link>https://6ix.com/company/aim-vaccine-co-ltd/news/aim-vaccines-mrna-rsv-vaccine-approved-for-us-clinical-trials</link>
<guid isPermaLink="true">https://6ix.com/company/aim-vaccine-co-ltd/news/aim-vaccines-mrna-rsv-vaccine-approved-for-us-clinical-trials</guid>
<pubDate>Thu, 27 Feb 2025 00:00:00 GMT</pubDate>
<description>The stocks in the Hong Kong pharmaceutical sector have recently shown an upward trend. As global capital flows positively into the pharmaceutical sector, PRC vaccine leader AIM Vaccine (06660.HK) announced on February 26 that its self-developed mRNA RSV (Respiratory Syncytial Virus) vaccine has recently received clinical trial approval from the U.S. Food and Drug Administration (FDA). The vaccine shows significantly higher humoral and cellular immunity compared to international marketed products</description>
</item>
<item>
<title>AIM Vaccine's mRNA Shingles Vaccine Submits Clinical Application to the U.S.</title>
<link>https://6ix.com/company/aim-vaccine-co-ltd/news/aim-vaccines-mrna-shingles-vaccine-submits-clinical-application-to-the-us</link>
<guid isPermaLink="true">https://6ix.com/company/aim-vaccine-co-ltd/news/aim-vaccines-mrna-shingles-vaccine-submits-clinical-application-to-the-us</guid>
<pubDate>Tue, 25 Feb 2025 00:00:00 GMT</pubDate>
<description>As global capital reassesses the investment value of innovative Chinese companies, the development of innovative vaccines in China is in full swing. On February 23, PRC vaccine leader AIM Vaccine (06660.HK) announced that its self-developed mRNA shingles vaccine has recently been submitted for clinical approval to the U.S. Food and Drug Administration (FDA). Not long ago, its mRNA RSV vaccine was also submitted for U.S. clinical trials. In just one month, AIM has made rapid progress in the globa</description>
</item>
<item>
<title>AIM Vaccine Integrates DeepSeek: Innovative Technology and Growth Potential Support Valuation Upside</title>
<link>https://6ix.com/company/aim-vaccine-co-ltd/news/aim-vaccine-integrates-deepseek-innovative-technology-and-growth-potential-support-valuation-upside</link>
<guid isPermaLink="true">https://6ix.com/company/aim-vaccine-co-ltd/news/aim-vaccine-integrates-deepseek-innovative-technology-and-growth-potential-support-valuation-upside</guid>
<pubDate>Mon, 24 Feb 2025 03:20:00 GMT</pubDate>
<description>AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on February 23, 2025, announced that the company is fully deploying the DeepSeek large model and promoting the application of DeepSeek R1 version across all business scenarios through localized strategies, achieving cost reduction, quality improvement, and efficiency enhancement throughout the vaccine lifecycle. This move opens up greater imagination for AIM Vaccine's value growth.</description>
</item>
</channel>
</rss>